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ABSTRACT 20 
Forskolin is a promising medicinal compound belonging to the plethora of specialized plant 21 
metabolites that constitutes a rich source of bioactive high-value compounds. A major obstacle for 22 
exploitation of plant metabolites is that they often are produced in low amounts and in plants 23 
difficult to cultivate. This may result in insufficient and unreliable supply leading to fluctuating and 24 
high sales prices. Hence, substantial efforts and resources have been invested in developing 25 
sustainable and reliable supply routes based on microbial cell factories. Here, we report microbial 26 
synthesis of (13R)-manoyl oxide, a proposed intermediate in the biosynthesis of forskolin and other 27 
medically important labdane-type terpenoids. Process optimization enabled synthesis of 28 
enantiomerically pure (13R)-manoyl oxide as the sole metabolite providing a pure compound in just 29 
two steps with a yield of 10 mg/l. The work presented here demonstrates the value of a standardized 30 
bioengineering pipeline and the large potential of microbial cell factories as sources for sustainable 31 
synthesis of complex biochemicals.  32 
  33 
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INTRODUCTION  34 
Terpenoids represent a highly diverse class of natural products with a multitude of applications in 35 
modern society ranging from renewable fuels to structurally complex medicinal compounds (1). For 36 
example they constitute the active compounds in several medicinal plant species including 37 
paclitaxel (Taxus brevifolia), forskolin (Coleus forskohlii) and artemisinin (Artemisia annua). 38 
Although several terpenoid derived natural products are currently in or have passed clinical trial for 39 
treatment of a number of conditions (2), sufficient supply of the molecules remains an obstacle. 40 
Purification from naturally producing plants has proven infeasible in many cases due to low yield, 41 
while establishment of heterologous production systems have been hampered by insufficient insight 42 
into the biosynthetic routes. However, the advent and rapid development of whole genome and 43 
transcriptome sequencing have paved the way for several recent breakthroughs. Particularly tissue 44 
specific metabolomics combined with RNA deep sequencing is an exceptionally promising 45 
approach for gene discovery in non-model organisms (3, 4).  46 
Our interest is focused on the diterpene forskolin produced by C. forskohlii. Forskolin is a 47 
promising pharmaceutical which has shown potential as treatment against a wide range of diseases 48 
(5-9). Forskolin is currently approved for treatment of glaucoma and heart-failure, while clinical 49 
trials against several forms of cancer are ongoing - the compound has been tested in over 800 50 
independent assays and in 76 cases forskolin was reported to be potently active (< 2 micro molar) 51 
including activity as D3 dopamine and relaxin receptor agonist, as allosteric activator of Mas 52 
related G-protein coupled receptor X1 and as antagonist of the androgen receptor (PubChem, 53 
accessed August 2014 http://pubchem.ncbi.nlm.nih.gov). Finally, forskolin is extensively used in 54 
basic research as an inhibitor of protein kinases (more than 50,000 publications in Web of Science, 55 
Thompson Reuters). Recently, the combined use of metabolomics and RNA deep sequencing were 56 
successfully applied to C. forskohlii root cells resulting in identification of two diterpene synthases, 57 
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CfTPS2 and CfTPS3, that catalyze the formation of (13R)-manoyl oxide (13R-MO) from 58 
geranylgeranyl diphosphate (GGPP) (10). 13R-MO is proposed to be the first dedicated 59 
intermediate in forskolin biosynthesis (11) .With this first biosynthetic knowledge in hand, 60 
establishment of a microbial system for further elucidation of the biosynthetic route as well as 61 
production of forskolin comes within reach.  62 
From a microbial engineering perspective, terpenoids constitute an attractive class of compounds as 63 
they are all derived from a single precursor, isopentenyl pyrophosphate (IPP), and its isomer 64 
dimethylallyl pyrophosphate (DMAPP). Substantial efforts have therefore been made in increasing 65 
IPP-supply as a driver for efficient terpenoid synthesis in microbes (12). IPP can be synthesized 66 
through two biochemical routes; the mevalonate (MEV), and the 1-deoxy-D-xylulose 5-phosphate 67 
(DXP) pathways, with the MEV-pathway being prevalent in eukaryotes and archea, while the DXP-68 
pathway dominates in eubacteria. While both routes have been subjected to numerous engineering 69 
efforts, the MEV-pathway has been most successfully applied in Escherichia coli (12, 13). One 70 
consensus minimal set of MEV-pathway enzymes required for boosting IPP/DMAPP supply can be 71 
formulated as mevalonate kinase (e.g. Saccharomyces cerevisiae [Sc] ERG12), phosphomevalonate 72 
kinase (e.g. ScERG8), mevalonate pyrophosphate decarboxylase (e.g. ScMVD1) and IPP isomerase 73 
(e.g. E. coli Idi2). Biosynthesis of diterpenes in E. coli faces the additional challenge that 74 
conversion of IPP to the general diterpene precursor, GGPP, is very inefficient in wild type E. coli 75 
strains and therefore requires introduction of a heterologous GGPP-synthase (14, 15). As previously 76 
shown for the C15 sesquiterpene amorphadiene, a substantial increase in product yield can be 77 
gained by combining a heterologous farnesyl diphosphate (FPP) synthase with the minimal 78 
consensus set of MEV-pathway genes (16). Likewise, high-level supply of GGPP in E. coli requires 79 
coordinated expression of a minimum of five genes: four for producing the precursor IPP/DMAPP 80 
(for example S. cerevisiae ERG12, ERG8, MVD1 and E. coli idi2), and one for a GGPP synthase. 81 
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As this consensus set is independent of the target diterpene, assembling all five genes on a single 82 
plasmid would substantially simplify experimental designs such as strain screenings. The Keasling 83 
group have reported the construction and verification of a single plasmid for synthesis of farnesyl 84 
diphosphate (13). Previous attempts of adaptation of this strategy for synthesis of GGPP 85 
unfortunately resulted in a non-functional plasmid (16). We have recently described a set of design 86 
principles for standardizing molecular cloning and formulation of a cloning pipeline to simplify 87 
multi-gene expression in E. coli (17). Here, we take advantage of this bioengineering pipeline to 88 
assemble and validate a single plasmid enabling GGPP synthesis from mevalonate, providing a 89 
versatile platform for diterpene biosynthesis in E. coli. By utilization of the platform, we achieve in 90 
vivo microbial synthesis of the proposed forskolin precursor 13R-MO. Through a limited series of 91 
iterative optimization steps, stereospecific synthesis of 13R-MO is achieved and yields are 92 
increased from trace amounts to 10 mg/l in micro-scale cultures. The final process yields 13R-MO 93 
in NMR-quality following a single, simple step for removal of impurities.   94 
  95 
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MATERIALS AND METHODS 96 
Bacterial strains and media. Escherichia coli strain NEB5α was used for cloning and propagation 97 
of plasmids. BL21(DE3) was used for radioactive labeling studies and KRX (Promega, Madison, 98 
USA) for production of 13R-MO. Following transformations, bacteria were propagated on Luria-99 
Bertoni (LB) agar plates supplemented with ampicillin (100 µg/ml), spectinomycin (50 µg/ml), 100 
kanamycin (50 µg/ml) or in combinations (ampicillin 50 µg/ml, spectinomycin 25 µg/ml, 101 
kanamycin 25 µg/ml) when required. Liquid cultures for plasmid preparation were based on 2xYT 102 
media, whereas pre-cultures for assays were prepared in LB media using antibiotic concentrations 103 
as described above. The PASM-5052 defined media used for expression assays were prepared as 104 
described by Studier (18) except for the exchange of Seleno methionine with methionine. For long 105 
term incubations (more than 24 h) ampicillin was replaced by carbencillin (50 µg/ml) as previously 106 
described (19). 107 
PCR and uracil-excision cloning. Uracil-excision compatible PCR products were produced with 108 
30 cycles in 50 µl reaction mixtures using proof-reading PfuX7 polymerase as previously described 109 
(20). Fragments of ScMVD1 (Gene ID: 855779), ScERG8 (Gene ID: 855260) and ScERG12 (Gene 110 
ID: 855248) were amplified from S. cerevisiae CEN.PK113-7D genomic DNA. Ecidi2 111 
(NC_000913) fragments were amplified from E. coli K12 MG1655 genomic DNA. CfTPS2 112 
(AWH04047.1) and CfTPS3 (AWH04048.1) were amplified from previously described constructs 113 
(10). AgGGPP (AF425235.2) was codon optimized for E. coli and synthetically synthesized 114 
(Genscript, Piscataway, USA). USER Fusion DNA assembly was performed essentially as 115 
described by Geu Flores et al (21). Purified PCR products of inserts and vector were mixed in a 116 
total insert to vector ratio of 6:1 (volume). When several DNA fragments were cloned 117 
simultaneously, use of equimolar amounts of each fragment was approximated by agarose gel 118 
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analysis. The reaction mixture was buffered with 5x Phusion HF buffer (Invitrogen) and 1 U of 119 
USER
TM
 enzyme mix (New England Biolabs, Ipswich, USA) was added. The reaction mixture was 120 
incubated for 20 min at 37°C, followed by 20 min at 25°C before transformation of chemically 121 
competent E. coli cells. All oligo nucleotides and synthetic genes used in this study are summarized 122 
in Table S1. 123 
 124 
Plasmid construction. The principle behind the molecular cloning of open reading frames (ORFs) 125 
is illustrated in Fig. 1 and described previously in detail in (17). Briefly, ORFs were PCR amplified 126 
without start- or stop-codons and flanked by 9 base pair linkers mediating standardized cloning into 127 
a pETDuet-1 (Merck KGaA, Darmstadt, Germany) backbone entry vector. Transcriptional units 128 
containing a T7-promoter, a consensus Shine-Dalgarno and the entry clone ORFs were re-amplified 129 
using generic oligo nucleotides with complementary linkers facilitating multi-fragment assemblies. 130 
Vector-backbones used in multi-fragment assemblies were likewise amplified with generic oligo 131 
nucleotides. All plasmids containing ORFs were verified by sequencing.  132 
 133 
35
S-methionine labeling of proteins. Transcription and translation of ORFs used in this study was 134 
confirmed in vivo by the rifampicin blocking technique and 
35
S-labeling (22). Briefly, pre-cultures 135 
of BL21 (DE3) cells carrying relevant plasmids were sub-cultured (1:50) into 1 ml chemically 136 
defined rich medium lacking methionine (18). Following induction of T7 dependent transcription 137 
by isopropyl-beta-D-1-thiogalactopyranoside and addition of rifampicin, cells were lysed and 138 
samples applied on precast 4-20% SDS-PAGE (Expedeon, San Diego, USA). Upon completion of 139 
the electrophoresis, the gels were dried and the labeled proteins were visualized using a CyclonePl 140 
scanner (Perkin Elmer, Waltham, USA). 141 
 142 
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Assay conditions. For chromatographic assays, bacteria from single plate colonies were inoculated 143 
into pre-cultures of 500 µl LB and grown 16 h at 37°C, 300 rpm shaking. For assaying manoyl 144 
oxide production, 40 µl LB pre-culture were inoculated into 2 ml freshly prepared PASM-5052 145 
defined media (1:50 dilution) and grown in 10 ml micro-titer plates at 37°C, 300 rpm to an OD of 146 
0.3. At this point, synthesis of recombinant proteins was induced by addition of rhamnose (1 mM) 147 
and IPTG (0,4 mM). Rhamnose stimulates synthesis of the T7-RNA polymerase in KRX whereas 148 
IPTG alleviates the lac-repressor from the lac operator present in all protein expression plasmids. 149 
Mevalonolactone (9mM) was added at this point, when required. All metabolite concentrations are 150 
given as the final concentration in the assay. After induction, cultures were incubated at either 151 
25°C, 150 rpm for 16 hours or 16°C, 150 rpm for 112 hours. Assays were performed with two 152 
independent colonies each analyzed in at least three replicates.  153 
 154 
Extraction procedure. Metabolite extraction was performed by the following procedure; 500 µl of 155 
bacterial culture was transferred to a 2 ml HPLC vial (Mikrolab, Aarhus, Denmark), prior to 156 
application of an overlay of 500 µl hexane containing internal standard (1-eicosene, 1 mg/l, Sigma-157 
Aldrich). Extractions were carried out at room temperature with shaking (240 rpm, table shaker 158 
(IKA-KS 130 basic)). After 1 or 16 h of extraction, 300 µl of the hexane phase were transferred to 159 
clean HPLC vials and subjected to gas chromatography analysis. Cultures for purification of 13R-160 
MO were performed as above except that the total volume (2 ml) of 240 cultures were pooled in a 2 161 
l Erlemeyer flask and extracted with 500 ml of hexane.  162 
 163 
Analytical method. Gas chromatography mass spectrometry (GC-MS) analysis was performed as 164 
previously described (23). Extracts were analyzed on a Shimadzu GCMS-QP2010 Ultra instrument 165 
with an Agilent HP-5MS column (30 m x 0.250 mm i.d., 0.25 µm film thickness) installed.  1 µl of 166 
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extract was injected in the injection port set at 250°C in splitless mode. The gasflow was set to 2.2 167 
ml/min and the purge flow to 1 ml/min, using helium as carrier gas. The GC program was set to: 168 
Hold for 1 min at 100°C, ramp 10°C/min to 250°C and a second ramp with 20°C/min to a final 169 
temperature of 310°C which was held for 2 min. Ion source and interface temperature were set to 170 
230°C and 150°C, respectively, and the solvent cutoff was set for 8 min. Mass analyzer was set in 171 
scan mode from 50 Hz to 350 Hz and a scan rate of 625 u/sec. Data analysis was carried out with 172 
the GCMS solution Version 2.50 SU3 (Shimadzu Cooperation). Compound identification was done 173 
by comparison to reference spectra databases (Wiley Registry of Mass Spectral Data, 8th Edition, 174 
July 2006, John Wiley & Sons, ISBN: 978-0-470-04785-9) and comparison of retention indices 175 
found in (23). 13R-MO was quantified relatively by comparison of TIC peak area normalized to the 176 
peak area of internal standard (1mg/l 1-eicosene). Absolute quantification was performed by 177 
comparison of normalized peak areas as above with the standard curve containing purified 13R-178 
MO. The standard curve was fitted with linear fit after log-log transformation. 179 
 180 
Single step purification of 13R-MO. The hexane extract was concentrated by rotor evaporation 181 
(Buchi, Switzerland) set to 35°C and 220 mbar. The concentrated sample was subsequently purified 182 
by solid phase extraction (Dual Layer Florisil/Na2SO4 6 ml PP SPE TUBE, Supelco Analytical, 183 
Sigma-Aldrich, St. Louis, USA) according to the manufacturers protocol. In brief, the sample was 184 
applied to the column, washed with hexane, before removal of residual solvent in a gentle nitrogen 185 
gas stream. The sample was eluted in deuterated chloroform (CDCl3) and analysed by NMR for 186 
structural verification  187 
 188 
NMR analysis and quantification. NMR analysis was performed using a 400 MHz Bruker Avance 189 
400 spectrometer, and the structure was confirmed by comparison of the observed 
1
H- and 
13
C-190 
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NMR spectra with literature data (24) (see Table 1) (25). CDCl3 was used was used as solvent. The 191 
amount of 13R-MO present in the NMR sample was determined by integration after adding 1.00 mg 192 
of dimethyl formamide (DMF). The integrals of one of the vinyl protons and one of the DMF 193 
methyl groups were used for the calculations. The NMR sample was subsequently used for creating 194 
a GCMS standard curve.  195 
 196 
197 
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RESULTS 198 
Assembly of a two-plasmid system for producing 13R-MO from mevalonolactone. Open 199 
reading frames (ORFs) of MEV-pathway genes from S. cerevisiae (ScERG12, ScERG8 and 200 
ScMVD1), IPP isomerase from E. coli (Ecidi2), GGPP synthase from Abies grandis (AgGGPPs) 201 
(26) and diterpene synthases from C. forskohlii (CfTPS2 and CfTPS3) (10) were initially cloned 202 
into an entry expression vector allowing assessment of proper expression and a standardized multi 203 
gene assembly (Fig. 1A). All plant derived ORFs were codon optimized for E. coli and truncated to 204 
remove plastid-targeting signals according to signal peptide predictions by the ChloroP-algorithm 205 
(27). Single ORF expression plasmids were transformed into BL21 (DE3) and transcription and 206 
translation was verified by 
35
S-methionine labeling in the presence of rifampicin as previously 207 
described (28) (Fig. S1). From these entry clones, ScMVD1, ScERG8, ScERG12, Ecidi2 and 208 
AgGGPPs were subsequently assembled into the plasmid pGGPP for GGPP synthesis, while 209 
CfTPS2 and CfTPS3 were assembled into pMO for conversion of GGPP into 13R-MO (Fig. 1B). In 210 
the setup employed here, the T7-promoter and a consensus Shine-Dalgarno sequence were 211 
maintained as transcriptional units in front of every ORF encoding the entry fragment in the 212 
assemblies (Fig. 1B).  213 
Co-transformation of pGGPP and pMO enables in vivo synthesis of 13R-MO. In order to 214 
establish the system and test the functionality of the plasmids, pMO was co-transformed with either 215 
a plasmid harboring the AgGGPP synthase alone (pSyn), pGGPP or an empty vector control 216 
(pCDFDuet-1) into the E. coli strain KRX. Subsequently assays were performed in a defined rich 217 
media based on lactose and glycerol (18). In order to test for pGGPP-mediated conversion of 218 
mevalonolactone to GGPP, cultures were split in two and mevalonolactone (9 mM) was 219 
supplemented to one culture containing pGGPP at the time of induction. After 16 h induction at 220 
25°C, non-polar metabolites were extracted with hexane and analyzed with gas chromatography 221 
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coupled to mass spectrometry (GC-MS). Consistent with previous findings (15), introduction of the 222 
AgGGPP synthase, either individually in pSyn or as part of pGGPP, enabled synthesis of trace 223 
amounts of two diterpene related compounds 1 and 2 (Fig. 2A and B). Supplementation of 224 
mevalonolactone to pGGPP containing cultures resulted in a modest, yet significant, increase in the 225 
yield of both compounds (Fig. 2C). The compounds were tentatively identified as 13R-MO and 226 
13S-MO, respectively, by comparison of mass spectra with the Wiley Registry of Mass Spectral 227 
Data, (8
th
 edition) (Fig. S2) as well as previously published data (23). Absolute identification of 228 
13R-MO by NMR was achieved using the final process described below (Table 1 and Fig. S3). To 229 
our knowledge, this is the first report of in vivo biosynthesis of 13R-MO, the proposed precursor for 230 
forskolin, in microbial systems and therefore an important milestone in efforts towards 231 
establishment of a microbial cell factory for forskolin synthesis. Moreover, the mevalonate 232 
mediated increase in diterpene synthesis strongly indicates that all enzymes required for conversion 233 
of mevalonate to GGPP are functionally expressed from pGGPP and this plasmid might therefore 234 
serve as a future platform for diterpene synthesis in E. coli. The observed co-occurrence of 13S-MO 235 
with 13R-MO has previously been associated with insufficient activity of the class I diTPS, 236 
CfTPS3, (10)  (see Fig. 2) and therefore indicated that the current process is sub-optimal.  237 
Process optimization facilitates increased yieldSeveral studies have demonstrated that substantial 238 
improvements of microbial production systems can be achieved using a simple set of process 239 
optimization steps including alteration of culture parameters and recovery procedures (13, 16, 29). 240 
Although no clear consensus protocol has emerged, several groups reported success with extended 241 
cultivation at low temperatures. Moreover, recovery by hexane extraction has previously been 242 
demonstrated to yield highly pure diterpene preparations from E. coli (16). A comparison between 243 
short incubation at medium temperature (16 h, 25°C) and longer incubation at low temperature (112 244 
h, 16°C) as well as between short (1 h) and extended (16 h) hexane extraction was undertaken. For 245 
13 
 
 
this experiment, E. coli KRX was transformed with pGGPP and pMO and all cultures were 246 
supplemented with mevalonolactone (9 mM) upon induction. Incubation as well as extraction time 247 
had a significant impact on diterpene yield when compared to the initial protocol contributing a 2-248 
fold yield increase each (Fig. 3). These yield improvements proved to be cumulative when 249 
combined resulting in an approximately 5-fold total increase over the initial protocol. Under these 250 
experimental conditions, the process, however, still resulted in formation of both 13S- and 13R-MO 251 
in approximately equal amounts. At this stage, the expression level of CfTPS3 from pMO was 252 
examined in detail. Remarkably, when pMO was transformed into BL21(DE3) and subjected to 
35
S-253 
methionine labeling, only CfTPS2 expression was detected (Fig. S1). Since it was already 254 
established that both CfTPS2 and CfTPS3 could be transcribed and translated in E. coli when 255 
expressed alone (Fig. S1), these findings indicated that transcription from the second T7 promoter is 256 
impeded in pMO. To test this hypothesis, we established a three-plasmid system consisting of 257 
pGGPP, pCfTPS2 and pCfTPS3. Indeed, when the three plasmids were co-transformed into E. coli 258 
KRX cells and cultivated in consistence with the optimal parameters identified above, biosynthesis 259 
of enantiomerically pure 13R-MO was obtained (Fig. 4A). Moreover, the flux through the pathway 260 
was dramatically increased resulting in a more than two thousand fold yield increase over the initial 261 
protocol.  262 
Recovery, structure validation and absolute quantification. An advantage of the E. coli based 263 
biosynthesis of diterpenes is high purity and therefore simple downstream processing. Indeed, with 264 
the hexane-based extraction utilized in this study, merely three compounds were observed with GC-265 
MS in addition to 13R-MO. Two of these (4 and 5), could be attributed to impurities arising from 266 
the instrument (data not shown) and are thus experimental artifacts rather than genuine compounds 267 
present in the extract. The one remaining metabolite, 3, was identified as indole by comparison of 268 
retention time and mass spectra with an authentic standard (Fig. 4B). Indole is known to be a 269 
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signaling molecule in E. coli with substantial influence on metabolism and membrane potential (30, 270 
31) and has been reported to inhibit terpene synthesis in E. coli (29). Thus elimination of indole 271 
formation might not only simplify recovery, but also increase yield. Recently, it was discovered that 272 
E. coli very efficiently converts extracellular tryptophan to indole (32). The defined media used in 273 
this study is supplemented with high concentrations (10 mM) of free amino acids, including 274 
tryptophan, to support high-level protein synthesis. Adjustment of the media composition by 275 
omission of tryptophan eliminated indole accumulation, resulting in an extract with 13R-MO as the 276 
sole metabolite observed by GC-MS analysis (Fig. 4A). Importantly, the overall yield of 13R-MO 277 
was unaffected. Following a simple removal of impurities by solid phase extraction, the recovered 278 
13R-MO was sufficiently pure for absolute identification by NMR analysis (see Table 1). The yield 279 
of the established process was quantified absolutely to 10 mg/l, by GC-MS using a standard curve 280 
of purified 13R-MO as reference. Typical dephosphorylation products (and result of endogenous 281 
phosphatase activity) of the pathway intermediates GGPP and 8-hydroxy-colaplol diphosphate are 282 
geranyl-geraniol and dihydroxy-copalol. Under the conditions used, both compounds are detectable 283 
with our analytical setup, yet no traces were found, indicating that those pathway intermediates do 284 
not accumulate. 285 
  286 
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DISCUSSION  287 
Biosynthesis of high-value terpenoids in microbial systems is emerging as an adequate 288 
and sustainable production platform, with several studies reporting yields of diterpene olefins in the 289 
scale of grams per liter (29, 33-35) (reviewed in (36)). A uniting feature of these studies is that 290 
yields in unoptimized micro-scale cultures are meagre, typical in the low milligram per liter range 291 
(0,15 mg/l, (33), 2,6 mg/l (16), 0,005 mg/l, (15), 4 mg/l, (35). A highly successful route for yield 292 
increase in micro-scale has been improvement of the pre-cursor pool by either introduction of the 293 
mevalonate pathway from yeast (13, 16, 35) or modulation of the endogenous MEP pathway by 294 
promoter engineering (29) or stacking of gene copies (33). Moreover, culture scale up into 295 
controlled bioreactors has proven essential obtaining gram scale yield (34, 35). Our aim is to use 296 
microbial systems for elucidation of biosynthetic pathways to high-value diterpenoids and 297 
simultaneously establish a microbial cell factory. Since gene discovery is likely to require a 298 
substantial screening effort, it was crucial for us to develop a process compatible with micro-scale 299 
cultures. We describe here the assembly of a single plasmid harboring five ORFs encoding enzymes 300 
sufficient for efficient GGPP synthesis from mevalonate in E. coli. Maintaining all these enzymatic 301 
functions on one plasmid substantially increases the flexibility in experimental design by serving as 302 
a platform to facilitate high throughput screening of novel diTPS candidates in different microbial 303 
strains. For our proof-of-principle, the process was optimized from affording trace amounts of two 304 
isomers, 13R-MO and 13S-MO, to obtaining 10 mg/l of enantiopure 13R-MO, corresponding to a 305 
more than two thousand fold increase. As such, our findings are comparable to previous findings 306 
regarding yield increase in micro-scale cultures (16, 33, 35), which hints that further engineering 307 
and culture scale up can substantially increase yield of 13R-MO, although the previously proposed 308 
cytotoxic effects (37-40) may represent a challenge.  However, our interest in 13R-MO is 309 
exclusively as a pre-cursor for forskolin, thus maintaining the micro-scale format is crucial at this 310 
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stage. Moreover, Ajikumar and co-workers observed that the strain developed for efficient 311 
production of the olefin taxadiene (1g/l) (29), merely produced 50mg/l of the next biosynthetic 312 
intermediate taxadien-5α-ol, thus indicating that careful balancing of enzyme activities might be 313 
most relevant once a complete pathway is assembled. We expect that the microbial synthesis 314 
process described here will serve as a foundation for full elucidation of the forskolin biosynthetic 315 
pathway by providing complex precursor molecules for in vitro assays and facilitate high-316 
throughput in vivo screening. In due course, the microbial process may also be developed into a cell 317 
factory for sustainable production of forskolin and other labdane-type terpenes. 318 
  319 
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FIGURES AND LEGENDS442 
 443 
FIG 1 Schematic overview of the gene assembly procedure. (A) Open reading frames are cloned 444 
individually into standardized entry expression vectors. (B) Assembly of pGGPP and pMO. 445 
Transcriptional units consisting of a T7-promoter, a consensus Shine-Dalgarno and the open 446 
reading frame are PCR amplified with generic oligo nucleotides that anneal outside the 447 
different ORFs in the flanking regions common to all entry plasmids. The generic oligo 448 
nucleotides facilitate specific assembly through defined linker regions (A-D, Eu, Ed). 449 
Transcriptional units are assembled in a single cloning reaction by USER Fusion. Start and stop 450 
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codons of open reading frames are indicated by green and red bars, respectively. T7 promoter 451 
and terminator are denoted pT7 and T7t, respectively 452 
 453 
FIG 2 In vivo synthesis of two manoyl oxide isomers in E. coli. (A) Total ion GC-MS 454 
chromatograms (TIC) of hexane extract from E. coli transformed with either pGGPP and pMO 455 
(top) or empty vectors (bottom). IS denotes the internal standard, 1mg/l 1-eicosene. (B) Mass 456 
spectra of metabolites 1 and 2 identified as 13R- and 13S-MO, respectively, based on 457 
comparison to the Wiley Registry of Mass Spectral Data (Fig.S2). (C) Relative quantification of 458 
13R- and 13S-MO synthesis in E. coli. Yields are normalized to a 1mg/l 1-Eicosene internal 459 
standard. N.d. indicates that neither 13R- nor 13S-MO were detectable. Numbers on the X-axis 460 
refer to the combination of plasmids present in the analyzed strain; 1 = pET-Duet/pCDF-Duet, 461 
2 = pMO/pCDF-Duet, 3 = pMO/pSyn, 4 = pMO/pGGPP, 5 = pET-Duet/pGGPP, 4+mev = 462 
pMO/pGGPP supplemented with 9 mM mevalonolactone. Data represents the average of four 463 
independent replicates with standard deviations. (D) Biosynthetic route to 13R-MO. Solid 464 
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arrows indicate enzymatic reactions. The enzymes catalyzing each step are depicted next to the 465 
reaction arrow. The dashed arrows indicate the intrinsic degradation of labda-13-en-8-ol 466 
diphosphate into equimolar amounts of 13R- and 13S-MO occurring in the absence of CfTPS3. 467 
Phosphate groups in the chemical structures are abbreviated with P.   468 
 469 
FIG 3 Impact of iterative improvements of culture conditions and extraction time on manoyl oxide 470 
yields. E. coli transformed with pGGPP and pMO was cultivated at either 25°C for 16 h post 471 
induction or at 16°C for 112 h post-induction. Cultures were extracted with hexane for either 1 472 
or 16 h. Graphs depict the average yields of the two manoyl oxide isomers from two 473 
independent colonies each analyzed in four independent replicates. Error bars denote standard 474 
deviation. 475 
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 476 
FIG 4. Identification and elimination of indole in E. coli extracts.  477 
Panel A displays Total Ion Chromatograms from GC-MS analysis of extracts from E. coli. The 478 
plasmid combination in question is listed in the top left corner of each chromatogram along 479 
with the initial concentration of tryptophan (trp) in the media. The metabolites observed were 480 
identified as 13R-MO (1), Indole (3) and impurities from the instrument (4 and 5∫). IS denotes 481 
the internal standard, 1mg/l 1-eicosene.  482 
Panel B; Total Ion chromatogram of authentic indole standard (top) as well as mass spectra of 483 
compound 3 (middle) and indole standard (bottom). Based on comparison of retention time and 484 
mass spectra with authentic standard, compound 3 was identified as indole.  485 
 486 
  487 
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 488 
A 
   
 
Gonzalez et al. (24) 
This 
work 
 # C ppm ppm M 
1 39,12 39,018 t 
2 18,62 18,564 t 
3 42,23 42,117 t 
4 33,32 33,238 s 
5 56,55 56,432 d 
6 20,03 19,956 t 
7 43,4 43,267 t 
8 75,09 75,091 s 
9 55,6 55,64 d 
10 37,11 37,011 s 
11 15,41 15,304 t 
12 35,73 35,714 t 
13 73,25 73,208 s 
14 148,07 147,976 d 
15 110,21 110,255 t 
16 28,71 28,556 q 
17 25,58 25,524 q 
18 33,4 33,362 q 
19 21,39 21,348 q 
20 15,41 15,421 q 
      489 
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B 
   
 
Gonzales et al.  
This 
work 
 
type ppm ppm 
Coupling 
constants 
-CH3 0,83 0,806 s 
-CH3 0,83 0,816 s 
-CH3 0,9 0,877 s 
-CH3 1,31 1,294 s 
-CH3 1,33 1,313 s 
=CH 4,94 4,938 q, J 11 & 2Hz 
=CH 5,16 5,164 q, J 17 & 2Hz 
=CH2 5,92 5,894 q, J 17 & 11Hz 
 490 
TABLE 1 A: 13 C-NMR spectra. Chemical shifts of annotated carbons of 13R-MO. B: 1H-NMR 491 
spectra. Chemical shifts of 1H in 13R-MO together with coupling constants. Reference spectra 492 
obtained from (24). 493 
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